Clinical Trial

Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 26, 2024 (before its estimated July 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is the first to explore the clinical study of neoadjuvant radiotherapy followed by chemotherapy combined with terriplizumab in breast cancer. Participants with locally advanced (T1c-T2(≥2cm) N1-2M0 or T3-4cN0-2M0) HR-positive and HER2-negative breast cancer were enrolled to evaluate the efficacy and safety of neoadjuvant radiotherapy followed by chemotherapy combined with triplimab in the treatment of locally advanced HR-positive and HER2-negative breast cancer. About 30 participants are planned to participate in this clinical study.
Trial Details
NCT Number NCT06705127
Lead Sponsor First Affiliated Hospital of Zhejiang University
Conditions HR-positive,HER2-negative Breast Cancer
Enrollment 30 participants
Start Date 2024-07-01
Primary Completion 2025-07-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-26